Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 289,821Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Sandostatin

PharmaCompass

01

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,439

2019 Revenue in Millions : 1,585

Growth (%) : -9

blank

02

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,413

2020 Revenue in Millions : 1,439

Growth (%) : -2

blank

03

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,238

2021 Revenue in Millions : 1,413

Growth (%) : -12

blank

04

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,314

2022 Revenue in Millions : 1,238

Growth (%) : 6

blank

05

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

06

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 1,650

2014 Revenue in Millions : 1,630

Growth (%) : -1%

blank

07

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 1,646

2015 Revenue in Millions : 1,630

Growth (%) : 1

blank

08

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 1,612

2016 Revenue in Millions : 1,646

Growth (%) : -2

blank

09

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 1,587

2017 Revenue in Millions : 1,612

Growth (%) : -2%

blank

10

Brand Name : Sandostatin

Octreotide

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Sandostatin

arrow
Fi Europe 2024
Not Confirmed

Octreotide

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 1,585

2018 Revenue in Millions : 1,587

Growth (%) : 0

blank